Sanjay Vashee, PhD

Director, Rockville Campus
Professor

Sanjay Vashee is a professor in the Synthetic Biology Group and the Rockville, MD Campus Director at the J. Craig Venter Institute. After joining JCVI in 2003, Dr. Vashee helped the Synthetic Biology Group develop synthetic genomics methods and technologies that led to the creation of a synthetic organism based on Mycoplasma mycoides subspecies capri. His research interests leverage these synthetic genomics technologies to better study and develop therapeutics for human and animal diseases.

Currently, Dr. Vashee is the Principal Investigator on a project funded by the NSF under the BREAD program to develop a more effective vaccine for contagious bovine pleuropneumonia (CBPP), an economically very important cattle disease that affects much of Africa, restricting trade and limiting the availability of protein sources for nutrition. He and his colleagues at INRA, France and UBERN, Switzerland are adapting the JCVI synthetic genomics technology to allow genetic manipulation of the CBPP pathogen, M. mycoides subspecies mycoides, expanding the mycoplasma genetic toolbox and using the latest genome sequencing platforms to identify virulence factors.

Together, these advances should help develop a more effective and safe vaccine based upon a rationally designed attenuated strain. Dr. Vashee also helps lead ongoing NIH funded projects that leverage synthetic genomics approaches to engineer large DNA viruses, including human herpesviruses on a genome-wide and combinatorial scale. Collaborators in these efforts include researchers at Johns Hopkins University School of Medicine (Herpes simplex virus 1 and Epstein Barr virus) as well as researchers at Tomegavax and Synthetic Genomics Vaccines, Inc. to develop a synthetic human cytomegalovirus vaccine. More recently, Dr. Vashee leads IDRC-funded efforts to develop genetic tools to manipulate African swine fever virus and DARPA-funded efforts to develop a Forensic Microbial System.

Prior to joining JCVI, Dr. Vashee was a postdoctoral fellow at Johns Hopkins University-School of Medicine where he was the first to characterize the in vitro DNA-binding properties of the human origin recognition complex, the initiator protein of eukaryotic DNA replication. Dr. Vashee holds a bachelor's degree in Biochemistry from the University of Illinois at Urbana-Champaign, a master's degree in Chemistry from Western Illinois University and a PhD in Biochemistry from the University of Texas at Austin.

Research Priorities

Development of therapeutics for viral diseases using synthetic genomics
  • Genome-wide engineering of human herpesviruses (herpes simplex virus 1, human cytomegalovirus and Epstein-Barr virus) to develop vaccines
  • Improving genetic tools for African swine fever virus to facilitate development of an effective vaccine
Development of vaccines for bacterial diseases using synthetic genomics
  • Generating safe vaccines for contagious bovine pleuropneumonia and contagious caprine pleuropneumonia based on live rationally attenuated strains
  • Exploring the use of M. mycoides subspecies capri as vector for animal bacterial and viral diseases

Designer Phage

Synthetic Engineering of Bacteriophage for Treatment of Wound Infections

Video

Viral Synthetic Genomics to Engineer Large dsDNA Viruses

Rapid engineering of large dsDNA viruses using synthetic genomics assembly tools.

Assembly of HSV-1

Use of cutting-edge synthetic genomics technology to revolutionize the study of herpesvirus biology.

26-Mar-2025
Press Release

Researchers design tools to develop vaccines more efficiently for African swine fever virus (ASFV)

The reverse-genetics system developed for ASFV may be adapted for other viruses, including lumpy skin disease, Zika, chikungunya, and Ebola viruses

28-Apr-2024
Chemical & Engineering News

Can CRISPR help stop African Swine Fever?

Gene editing could create a successful vaccine to protect against the viral disease that has killed close to 2 million pigs globally since 2021.

30-Jan-2024
Press Release

J. Craig Venter Institute contracted by the Centers for Disease Control and Prevention to rapidly construct synthetic influenza genes

Genes will be used to help develop seasonal and pandemic vaccines, improving response time and vaccine efficacy

23-Feb-2023
Collaborator Release

BullFrog AI Partners with J. Craig Venter Institute to Develop Colorectal Cancer Therapeutic

Collaboration seeks to develop an oncolytic virus that incorporates a novel, precision-targeted approach to improve safety and efficacy

21-Jul-2022
Press Release

Synthetic genomics advances and promise

Advances in DNA synthesis will enable extraordinary new opportunities in medicine, industry, agriculture, and research

13-Jan-2022
Press Release

Omicron and Beta variants evade antibodies elicited by vaccines and previous infections, but boosters help

Pregnancy also contributes to a reduced COVID-19 antibody response

20-Aug-2009
Press Release

J. Craig Venter Institute Researchers Clone and Engineer Bacterial Genomes in Yeast and Transplant Genomes Back into Bacterial Cells

New methods allow for the rapid engineering of bacterial chromosomes and the creation of extensively modified bacterial species; should also play key role in boot up of synthetic cell